Abstract
Immune-related adverse events (irAE) are inevitable following immunotherapy, which significantly impact the quality of life and possibly cause therapy discontinuation or interruption in cancer patients. Previous studies reported that T-cell receptor beta variable (TRBV) gene was related to irAE in Caucasian patients with non-small cell lung cancer (NSCLC). However, the relationship between TRBV gene and irAE remains to be revealed in Chinese NSCLC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
